Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + NCRT for Locally Advanced Rectal Cancer
NCT06312982Phase 3Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in rectal cancer (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Complete Response. Started Mar 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06312982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312982.